Neuronetics, Inc.STIMEarnings & Financial Report
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Revenue
$18.5M
Gross Profit
$14.0M
Operating Profit
$-7.7M
Net Profit
$-13.3M
Gross Margin
75.6%
Operating Margin
-41.7%
Net Margin
-72.0%
YoY Growth
92550.0%
EPS
$-0.44
Neuronetics, Inc. Q3 FY2024 Financial Summary
Neuronetics, Inc. reported revenue of $18.5M (up 92550.0% YoY) for Q3 FY2024, with a net profit of $-13.3M (-72.0% margin). Cost of goods sold was $4.5M, operating expenses totaled $21.7M.
Key Financial Metrics
| Total Revenue | $18.5M |
|---|---|
| Net Profit | $-13.3M |
| Gross Margin | 75.6% |
| Operating Margin | -41.7% |
| Report Period | Q3 FY2024 |
Neuronetics, Inc. Annual Revenue by Year
Neuronetics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $149.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $149.2M |
| 2024 | $74.9M |
| 2023 | $33.3M |
| 2022 | $65.2M |
Neuronetics, Inc. Quarterly Revenue & Net Profit History
Neuronetics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $41.8M | +85.7% | $-7.2M | -17.2% |
| Q3 FY2025 | $37.3M | +101.3% | $-9.0M | -24.3% |
| Q2 FY2025 | $38.1M | +131.7% | $-10.1M | -26.6% |
| Q1 FY2025 | $32.0M | +83.6% | $-12.7M | -39.6% |
| Q4 FY2024 | $22.5M | +22393.0% | $-12.7M | -56.4% |
| Q3 FY2024 | $18.5M | +92550.0% | $-13.3M | -72.0% |
| Q2 FY2024 | $16.4M | -6.6% | $-9.8M | -59.8% |
| Q1 FY2024 | $17.4M | +12.1% | $-7.9M | -45.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $16.4M | $18.5M | $22.5M | $32.0M | $38.1M | $37.3M | $41.8M |
| YoY Growth | 12.1% | -6.6% | 92550.0% | 22393.0% | 83.6% | 131.7% | 101.3% | 85.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $103.8M | $96.8M | N/A | $140.9M | $142.0M | $134.7M | $145.5M | $141.6M |
| Liabilities | $76.2M | $77.4M | N/A | $109.1M | $102.5M | $103.1M | $114.1M | $115.3M |
| Equity | $27.7M | $19.4M | $9.4M | $27.7M | $35.5M | $27.1M | $27.4M | $22.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-12.0M | $-5.0M | $-5.4M | $-8.6M | $-17.0M | $-3.5M | $-785000 | $908000 |